Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data

IMPORTANCE: Little is known about the heterogeneity in low-density lipoprotein cholesterol levels (LDL-C) lowering with proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor medications. OBJECTIVE: To evaluate the interindividual variability in LDL-C reduction with the PCSK9 inhibitor drug evol...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Cardiol
Main Authors: Qamar, Arman, Giugliano, Robert P., Keech, Anthony C., Kuder, Julia F., Murphy, Sabina A., Kurtz, Christopher E., Wasserman, Scott M., Sever, Peter S., Pedersen, Terje R., Sabatine, Marc S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Brief Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439677/
https://ncbi.nlm.nih.gov/pubmed/30540337
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2018.4178
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados